Akira Mita Selected Research

1- (3- C- ethynylribopentofuranosyl)cytosine

5/2012	A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors.
2/2012	Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
6/2010	An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Akira Mita Research Topics

Disease

6	Neoplasms (Cancer) 05/2012 - 09/2006
2	Peripheral Nervous System Diseases (PNS Diseases) 05/2012 - 02/2012
1	Pain (Aches) 05/2012
1	Hypesthesia (Numbness) 05/2012
1	Hyperesthesia 05/2012
1	Tremor (Tremors) 05/2012
1	Vomiting 02/2012
1	Nausea 02/2012
1	Asthenia 02/2012
1	Anorexia 02/2012
1	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 06/2010

Drug/Important Bio-Agent (IBA)

3	1- (3- C- ethynylribopentofuranosyl)cytosineIBA 05/2012 - 06/2010
3	trifluridine tipiracil drug combinationIBA 10/2008 - 09/2006
2	Pharmaceutical PreparationsIBA 05/2012 - 02/2012
2	NucleosidesIBA 02/2012 - 06/2010
1	RNA Polymerase I (Polymerase I, RNA)IBA 02/2012
1	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 02/2012
1	Ribose (D-Ribose)IBA 06/2010
1	CytidineIBA 06/2010
1	RNA (Ribonucleic Acid)IBA 06/2010
1	Trifluridine (Viroptic)FDA LinkGeneric 10/2008
1	ThymidineIBA 10/2008

Therapy/Procedure

2	Oral Administration 10/2008 - 09/2006
1	Intravenous Administration 05/2012
1	Therapeutics 09/2006